2024
Cost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight
Kopp P, Yang C, Yang H, Katz J, Paltiel A, Hunter D, Callahan L, Mihalko S, Newman J, DeVita P, Loeser R, Miller G, Messier S, Losina E. Cost‐Effectiveness of Community‐Based Diet and Exercise for Patients with Knee Osteoarthritis and Obesity or Overweight. Arthritis Care & Research 2024, 76: 1018-1027. PMID: 38450873, DOI: 10.1002/acr.25323.Peer-Reviewed Original ResearchBody mass indexUsual careQuality-adjusted life yearsHealth educationIncremental cost-effectiveness ratioKnee osteoarthritisKnee OAGroup-based health educationWestern Ontario and McMaster Universities Osteoarthritis Index pain scoreLifetime costsOA careE programCost-effectiveIncremental cost-effectivenessFunctional limitationsIncreased lifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioLife yearsMass indexPain reductionSocietal perspectiveCohort characteristicsKneeExercise
2023
Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity
Kostic AM, Leifer VP, Selzer F, Hunter DJ, Paltiel AD, Chen AF, Robinson MK, Neogi T, Collins JE, Messier SP, Edwards RR, Katz JN, Losina E. Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity. Arthritis Care & Research 2023, 75: 1752-1763. PMID: 36250415, PMCID: PMC10375659, DOI: 10.1002/acr.25044.Peer-Reviewed Original ResearchConceptsLaparoscopic sleeve gastrectomyClass III obesityIncremental cost-effectiveness ratioTotal knee replacementQuality-adjusted life expectancyWeight loss interventionProbabilistic sensitivity analysesKnee replacementNonsurgical weight loss interventionsLong-term clinical benefitWeight lossKnee osteoarthritis patientsWeight loss strategiesHealth care sector perspectiveOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioWeight loss/Gastric bypassSleeve gastrectomyPrimary outcomeLoss interventionOsteoarthritis patientsClinical benefitHigher complications
2022
Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis
Bensen G, Rogers A, Leifer V, Edwards R, Neogi T, Kostic A, Paltiel A, Collins J, Hunter D, Katz J, Losina E. Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. Osteoarthritis And Cartilage 2022, 31: 279-290. PMID: 36414225, PMCID: PMC9892279, DOI: 10.1016/j.joca.2022.07.013.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioKnee osteoarthritisUsual careNociplastic painCumulative quality-adjusted life yearsMore quality-adjusted life yearsNeuropathic pain syndromesDirect medical costsOsteoarthritis Policy ModelLifetime direct medical costsCost-effectiveness ratioCost-effectiveness analysisOA carePainDETECT questionnairePain syndromeCost‐Effectiveness of Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
Williams EE, Katz JN, Leifer VP, Collins JE, Neogi T, Suter LG, Levy B, Farid A, Safran‐Norton C, Paltiel AD, Losina E. Cost‐Effectiveness of Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear. ACR Open Rheumatology 2022, 4: 853-862. PMID: 35866194, PMCID: PMC9555200, DOI: 10.1002/acr2.11480.Peer-Reviewed Original ResearchArthroscopic partial meniscectomyIncremental cost-effectiveness ratioCost-effectiveness ratioInitial physical therapyOptional surgeryPhysical therapyPartial meniscectomyMeniscal tearsImmediate surgeryTreatment optionsHigh incremental cost-effectiveness ratioConcomitant meniscal tearsOsteoarthritis Research (MeTeOR) trialDegenerative meniscal tearsOsteoarthritis Policy ModelMonte Carlo microsimulationProbabilistic sensitivity analysesBase-case assumptionsSurgery efficacyPersistent painKnee osteoarthritisPost surgeryTreatment strategiesSurgery strategySurgerySocietal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Huizinga JL, Stanley EE, Sullivan JK, Song S, Hunter DJ, Paltiel AD, Neogi T, Edwards RR, Katz JN, Losina E. Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States. Arthritis Care & Research 2022, 74: 1349-1358. PMID: 33629485, PMCID: PMC8382774, DOI: 10.1002/acr.24581.Peer-Reviewed Original ResearchConceptsSymptomatic knee osteoarthritisOpioid use disorderOpioid useMcMaster Universities Osteoarthritis Index (WOMAC) pain scoreSymptomatic knee osteoarthritis patientsLong-term pain managementProlonged opioid usePublic health causeStrong opioid useSocietal costsKnee osteoarthritis patientsSocietal economic burdenDirect medical costsMedicare Current Beneficiary SurveyOsteoarthritis Policy ModelCriminal justice costsOUD prevalencePain scoresSD ageOpioid regimensPain managementKnee osteoarthritisOsteoarthritis patientsWestern OntarioMedical costs
2021
The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis.
Chen AT, Bronsther CI, Stanley EE, Paltiel AD, Sullivan JK, Collins JE, Neogi T, Katz JN, Losina E. The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2021, 174: 747-757. PMID: 33750190, PMCID: PMC8288249, DOI: 10.7326/m20-4722.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioBody mass indexTotal knee replacementKnee replacementCost-effectiveness analysisTKR recipientsKnee osteoarthritisMass indexEnd-stage knee osteoarthritisLong-term clinical benefitCost-effective strategyPreoperative pain levelNational InstituteOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioBase-case analysisProbabilistic sensitivity analysesMultiple comorbiditiesCost-effectiveness perspectivePain levelsComplication rateClinical benefitCardiovascular diseaseMedical costs
2019
Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis
Smith KC, Losina E, Messier SP, Hunter DJ, Chen AT, Katz JN, Paltiel AD. Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis. ACR Open Rheumatology 2019, 2: 26-36. PMID: 31943972, PMCID: PMC6957917, DOI: 10.1002/acr2.11090.Peer-Reviewed Original ResearchKnee osteoarthritisMedicare plansIntensive dietKnee OA treatmentIncidence of comorbiditiesCommercial insurance plansHealth promotion interventionsMedicare-eligible individualsOsteoarthritis Policy ModelTotal knee replacementCommercial plansObese patientsOpioid useMore patientsExercise programArthritis trialsKnee replacementMedicare Advantage plansOsteoarthritisOA treatmentBudget impactMedical expendituresInsurance plansPatientsDietCost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2018
Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement
Smith KC, Paltiel AD, Yang HY, Collins JE, Katz JN, Losina E. Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement. Osteoarthritis And Cartilage 2018, 26: 1495-1505. PMID: 30092263, PMCID: PMC6202236, DOI: 10.1016/j.joca.2018.07.014.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesFinancial incentivesOne-way sensitivity analysesDeterministic sensitivity analysesCost-effectiveness ratioSensitivity analysisCost-effectiveness outcomesOsteoarthritis Policy ModelEfficacy of THCKnee replacement recipientsPolicy modelLife yearsTelephonic health coachingQALYHealthcare perspective
2016
Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis
Smith SR, Katz JN, Collins JE, Solomon DH, Jordan JM, Suter LG, Yelin EH, Paltiel AD, Losina E. Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care & Research 2016, 69: 234-242. PMID: 27111538, PMCID: PMC5378156, DOI: 10.1002/acr.22916.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsOA patientsTKA outcomesKnee OA patientsKnee osteoarthritis treatmentInfluence of opioidsOsteoarthritis Policy ModelCost-effectiveness ratioConservative treatmentPain reductionPain reliefPersistent painKnee osteoarthritisMean ageTKA utilizationTreatment optionsOsteoarthritis treatmentLife yearsOxycodoneTramadolTKALifetime costsOpioidsOutcomes
2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injectionLifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty
Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, Walensky RP, Katz JN. Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty. Arthritis Care & Research 2015, 67: 203-215. PMID: 25048053, PMCID: PMC4422214, DOI: 10.1002/acr.22412.Peer-Reviewed Original ResearchConceptsTotal knee arthroplastyDirect medical costsOA patientsKnee osteoarthritisMedical costsKnee arthroplastyTKA utilizationEligibility criteriaEffective nonoperative therapiesKellgren/LawrenceKnee osteoarthritis managementKnee OA patientsSymptomatic knee osteoarthritisMulticenter Osteoarthritis StudyLifetime costsUtilization Project dataOsteoarthritis Policy ModelLifetime direct medical costsLifetime medical costsHealth care costsMedicare reimbursement schedulesTotal lifetime costsNonoperative therapySymptomatic osteoarthritisOsteoarthritis management
2013
Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
Losina E, Daigle ME, Suter LG, Hunter DJ, Solomon DH, Walensky RP, Jordan JM, Burbine SA, Paltiel AD, Katz JN. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthritis And Cartilage 2013, 21: 655-667. PMID: 23380251, PMCID: PMC3670115, DOI: 10.1016/j.joca.2013.01.016.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsTotal knee replacementPain reliefMajor toxicityRevision total knee replacementCare sequenceConservative pain managementGuideline-concordant careKnee OA treatmentQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioCorticosteroid injectionKnee OAKnee osteoarthritisPain managementOsteoarthritis drugsKnee replacementDMOADsOA treatmentLife yearsProgressionLife expectancyRelief